findmyKOL
Clinical trialNCT00747253CompletedPhase 1Interventional

Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors

SponsorMonteris MedicalEnrollment10Brain CancerBrain NeoplasmBrain TumorBrain Tumor, RecurrentGlioblastoma MultiformeRecurrent Glioblastoma Multiforme
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Cleveland Clinic Foundation, 9500 Euclid Ave

    Cleveland, Ohio, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2008
Primary completion
31 Oct 2009
Completion
30 Apr 2010
Last update posted
24 Aug 2021
Registered enrollment
10
Registry id
NCT00747253

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.